Editorial |

Intravitreal Corticosteroid Therapy:  Putting the Problem of Glaucoma in Perspective

Dennis P. Han, MD; Dale K. Heuer, MD
Arch Ophthalmol. 2012;130(3):380-382. doi:10.1001/archopthalmol.2011.1097.
Text Size: A A A
Published online


Intravitreal corticosteroid therapy may be useful for a variety of retinal and ocular inflammatory conditions. Randomized clinical trials have shown its benefits in macular edema due to retinal vein occlusion.1,2 Sustained-release devices of fluocinolone acetonide and dexamethasone have made possible continuous and long-duration delivery of intravitreal corticosteroids for conditions such as diabetic macular edema3 and chronic idiopathic uveitis.4 However, as the duration of exposure to corticosteroids increases, so do the cumulative risks of cataract and glaucoma, as well as rarer effects of local immunosuppression, such viral retinitis.5 Although cataracts can be removed with a high success rate, corticosteroid-associated intraocular pressure (IOP) elevation carries risks of glaucomatous optic atrophy, and its management raises concerns of catastrophic visual loss from surgical complications, such as late-onset, bleb-related endophthalmitis. Nevertheless, it is the editorialists' impression that intravitreal corticosteroid therapy may be underutilized because of a fear of IOP elevation or of its potentially attendant surgical interventions, a fear that is disproportionate to actual risk. Consequently, our aim is to provide perspective on the risk-to-benefit ratio of intravitreal corticosteroid therapy with respect to corticosteroid-associated glaucoma. Physicians' cognitive biases, which can also thwart good decision making, will be discussed.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles